Advertisement
XOM vs XRAY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is XOM is a Buy and XRAY is a Buy.
Momentum Indicator for XOM turns positive, indicating new upward trend
XOM saw its Momentum Indicator move above the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 59 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XOM just turned positive on October 06, 2026. Looking at past instances where XOM's MACD turned positive, the stock continued to rise in 30 of 50 cases over the following month. The odds of a continued upward trend are 60%.
Following a +3.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where XOM advanced for three days, in 232 of 373 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 192 of 312 cases where XOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for XOM moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 27 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XOM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.
XOM broke above its upper Bollinger Band on October 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 26, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. XOM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XOM's P/B Ratio (2.852) is slightly higher than the industry average of (1.707). XOM has a moderately high P/E Ratio (23.154) as compared to the industry average of (11.466). Projected Growth (PEG Ratio) (1.392) is also within normal values, averaging (1.088). Dividend Yield (0.023) settles around the average of (0.047) among similar stocks. P/S Ratio (1.911) is also within normal values, averaging (3.764).
XRAY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for XRAY turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 32 of 53 cases over the following month. The odds of a continued upward trend are 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XRAY's RSI Indicator exited the oversold zone, 21 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 49 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
Following a +7.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for XRAY moved below the 200-day moving average on September 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
XRAY broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.361) is normal, around the industry mean (4.942). P/E Ratio (-3.377) is within average values for comparable stocks, (37.224). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.069) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
XOM | XRAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 4 | 100 | |
SMR RATING 1..100 | 62 | 97 | |
PRICE GROWTH RATING 1..100 | 6 | 64 | |
P/E GROWTH RATING 1..100 | 10 | 16 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (6) in the Medical Specialties industry is significantly better than the same rating for XOM (85) in the Integrated Oil industry. This means that XRAY’s stock grew significantly faster than XOM’s over the last 12 months.
XOM's Profit vs Risk Rating (4) in the Integrated Oil industry is significantly better than the same rating for XRAY (100) in the Medical Specialties industry. This means that XOM’s stock grew significantly faster than XRAY’s over the last 12 months.
XOM's SMR Rating (62) in the Integrated Oil industry is somewhat better than the same rating for XRAY (97) in the Medical Specialties industry. This means that XOM’s stock grew somewhat faster than XRAY’s over the last 12 months.
XOM's Price Growth Rating (6) in the Integrated Oil industry is somewhat better than the same rating for XRAY (64) in the Medical Specialties industry. This means that XOM’s stock grew somewhat faster than XRAY’s over the last 12 months.
XOM's P/E Growth Rating (10) in the Integrated Oil industry is in the same range as XRAY (16) in the Medical Specialties industry. This means that XOM’s stock grew similarly to XRAY’s over the last 12 months.
| XOM | XRAY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 66% | 1 day ago 50% |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 60% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 74% |
| Advances ODDS (%) | 3 days ago 62% | 7 days ago 59% |
| Declines ODDS (%) | 9 days ago 44% | 3 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 62% | 1 day ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
XOM’s FA Score shows that 3 FA rating(s) are green while XRAY’s FA Score has 2 green FA rating(s).
- XOM’s FA Score: 3 green, 2 red.
- XRAY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
XOM’s TA Score shows that 4 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).
- XOM’s TA Score: 4 bullish, 4 bearish.
- XRAY’s TA Score: 4 bullish, 5 bearish.
Price Growth
XOM (@Integrated Oil) experienced а +1.15% price change this week, while XRAY (@Pharmaceuticals: Other) price change was +5.41% for the same time period.
The average weekly price growth across all stocks in the @Integrated Oil industry was -1.90%. For the same industry, the average monthly price growth was +3.55%, and the average quarterly price growth was +3.00%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.35%. For the same industry, the average monthly price growth was -3.01%, and the average quarterly price growth was +10.29%.
Reported Earning Dates
XOM is expected to report earnings on Oct 30, 2026.
XRAY is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Integrated Oil (-1.90% weekly)Integrated oil companies are involved across nearly the entire oil value chain – from upstream operations like exploration and production, to downstream functions of refining and marketing. Exxon Mobil Corporation, Chevron Corporation and BP are major integrated oil companies. Their bottom lines’ response to crude oil prices could depend on the proportion of upstream vs. downstream businesses; for example, if a company has substantial downstream business, the adverse impact on their upstream business due to falling crude prices could be mitigated by benefits to its downstream business.
@Pharmaceuticals: Other (+0.35% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
XRAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
|---|---|---|---|---|
| XRAY | 100% | +1.41% | ||
| NVST - XRAY | 62% Loosely correlated | -0.34% | ||
| ALGN - XRAY | 58% Loosely correlated | -0.20% | ||
| QDEL - XRAY | 50% Loosely correlated | -1.31% | ||
| KIDS - XRAY | 48% Loosely correlated | -0.83% | ||
| STE - XRAY | 46% Loosely correlated | -0.71% | ||
More | ||||